Nanjing Pharmaceutical announced that the registration amount of 6 billion yuan of ultra-short-term financing notes approved by the company in October 2024 will expire in October 2026. It plans to continue to apply to the China Interbank Market Dealers Association to register and issue ultra-short-term financing notes of no more than 6 billion yuan. The issuance period will not exceed 270 days, and the funds raised will be used to supplement working capital or replace interest-bearing liabilities. In addition, Zuo Xiangyuan, a non-independent director of the company, resigned due to job changes, and the controlling shareholder nominated Huang Cheng as a candidate for non-independent director of the 10th board of directors. The relevant bill will be submitted to the 4th Extraordinary General Meeting of Shareholders in 2026 for review.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.